SG11201603165TA - Novel Peptide Having 4 Linked CTL Epitopes - Google Patents
Novel Peptide Having 4 Linked CTL EpitopesInfo
- Publication number
- SG11201603165TA SG11201603165TA SG11201603165TA SG11201603165TA SG11201603165TA SG 11201603165T A SG11201603165T A SG 11201603165TA SG 11201603165T A SG11201603165T A SG 11201603165TA SG 11201603165T A SG11201603165T A SG 11201603165TA SG 11201603165T A SG11201603165T A SG 11201603165TA
- Authority
- SG
- Singapore
- Prior art keywords
- ctl epitopes
- novel peptide
- linked ctl
- linked
- peptide
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013218524 | 2013-10-21 | ||
JP2014155132 | 2014-07-30 | ||
PCT/JP2014/077807 WO2015060235A1 (en) | 2013-10-21 | 2014-10-20 | Novel four-ctl epitope-joined peptide |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201603165TA true SG11201603165TA (en) | 2016-05-30 |
Family
ID=52992831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201603165TA SG11201603165TA (en) | 2013-10-21 | 2014-10-20 | Novel Peptide Having 4 Linked CTL Epitopes |
Country Status (19)
Country | Link |
---|---|
US (1) | US10137183B2 (en) |
EP (1) | EP3061771B1 (en) |
JP (2) | JP6211093B2 (en) |
KR (1) | KR101913333B1 (en) |
CN (1) | CN105658673B (en) |
AU (1) | AU2014337643B2 (en) |
CA (1) | CA2927817C (en) |
DK (1) | DK3061771T3 (en) |
ES (1) | ES2796301T3 (en) |
HU (1) | HUE050164T2 (en) |
MX (1) | MX2016004754A (en) |
MY (1) | MY179119A (en) |
PH (1) | PH12016500742A1 (en) |
PL (1) | PL3061771T3 (en) |
PT (1) | PT3061771T (en) |
RU (1) | RU2636549C1 (en) |
SG (1) | SG11201603165TA (en) |
TW (1) | TWI651094B (en) |
WO (1) | WO2015060235A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104926944B (en) * | 2015-05-22 | 2018-04-13 | 北京康爱瑞浩生物科技股份有限公司空港分公司 | Multitarget composite antigen load C D8+The preparation method and its usage of cytotoxic T lymphocyte |
US20200353070A1 (en) * | 2018-01-22 | 2020-11-12 | Japan As Represented By The Director-General Of National Institute Of Infectious Diseases | Selective cd8-positive t cell-inducing vaccine antigen |
JP6716801B2 (en) * | 2018-06-29 | 2020-07-01 | 大鵬薬品工業株式会社 | Antitumor agent and evaluation method thereof |
SG11202104416YA (en) * | 2018-11-02 | 2021-05-28 | Taiho Pharmaceutical Co Ltd | Emulsion formulation and method for preparing the same |
AU2020411439A1 (en) * | 2019-12-26 | 2022-08-04 | Taiho Pharmaceutical Co., Ltd. | Agent for adjuvant therapy |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9340577B2 (en) * | 1992-08-07 | 2016-05-17 | Epimmune Inc. | HLA binding motifs and peptides and their uses |
US20080286228A1 (en) | 1995-10-20 | 2008-11-20 | Tarantolo Stefano R | Compositions and methods for enhancing immune responses mediated by antigen-presenting cells |
ATE406913T1 (en) | 1996-03-10 | 2008-09-15 | Meiji Dairies Corp | PEPTIDE-BASED IMMUNOTHERAPEUTIC AGENT AGAINST ALLERGIES |
JP4138073B2 (en) * | 1998-05-08 | 2008-08-20 | 株式会社グリーンペプタイド | Human cancer regression antigen protein |
ATE375362T1 (en) | 1998-06-25 | 2007-10-15 | Kyogo Itoh | TUMOR ANTIGEN PEPTIDES DERIVED FROM CYCLOPHILIN B |
KR100660367B1 (en) | 1998-08-28 | 2006-12-21 | 교고 이또 | Novel tumor antigen protein sart-3 and tumor antigen peptide thereof |
US6667037B1 (en) | 1998-10-09 | 2003-12-23 | Ludwig Institute For Cancer Research | Isolated peptides which bind to HLA-B35 molecules, larger peptides which contain these, nucleic acid molecules encoding peptides, and uses thereof |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
ES2340357T3 (en) * | 1999-08-05 | 2010-06-02 | Green Peptide Co., Ltd. | TUMOR ANTIGEN. |
JP2003512057A (en) | 1999-10-19 | 2003-04-02 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | MAGE-A12 antigen peptide and use thereof |
WO2001041741A1 (en) | 1999-12-13 | 2001-06-14 | Epimmune Inc. | Hla class i a2 tumor associated antigen peptides and vaccine compositions |
AU2000261861A1 (en) * | 2000-07-28 | 2002-02-13 | Hanmi Pharm. Co., Ltd. | Gene expression system for mass production of hepatitis c viral rna-dependent rna polymerase and enzyme assay using fusion protein expressed therefrom |
EP1306431B1 (en) | 2000-07-31 | 2008-03-19 | Green Peptide Co., Ltd. | Tumor antigen |
JP4097178B2 (en) * | 2000-10-03 | 2008-06-11 | 株式会社グリーンペプタイド | Tumor antigen |
WO2003025569A1 (en) | 2001-09-18 | 2003-03-27 | Kyogo Itoh | Method of detecting cellular immunity and application thereof to drugs |
EP1557466B1 (en) | 2002-09-27 | 2009-09-02 | Dainippon Sumitomo Pharma Co., Ltd. | Tumor antigen protein and utilization thereof |
AU2003280688A1 (en) * | 2003-10-31 | 2005-05-19 | Kurume University | Combination therapy of peptide vaccination and estramustine treatment |
JP4579581B2 (en) * | 2003-12-08 | 2010-11-10 | 株式会社グリーンペプタイド | HLA-A24 or HLA-A2 binding peptide of parathyroid hormone related protein |
CA2554195C (en) | 2004-01-23 | 2011-02-22 | Green Peptide Co., Ltd. | Peptide originating in epidermal growth factor receptor (egfr) |
US20080014186A1 (en) | 2004-05-26 | 2008-01-17 | Green Peptide Co., Ltd. | Hla-A24 or Hla-A2 Binding Peptides of Parathyroid Hormone-Related Protein |
JP4547197B2 (en) | 2004-06-30 | 2010-09-22 | 公正 安元 | Cancer specific tumor antigen |
JP2006188507A (en) | 2004-12-10 | 2006-07-20 | Tokyo Univ Of Agriculture & Technology | Method for improving solubility of protein |
BRPI0619255B8 (en) | 2005-11-30 | 2021-05-25 | Chugai Seiyaku Kabishiki Kaisha | peptide compound, pharmaceutical composition, use of compound and drug for cancer immunotherapy |
JP5114403B2 (en) | 2006-07-11 | 2013-01-09 | 株式会社グリーンペプタイド | SART3-derived peptides useful for cancer vaccine therapy for HLA-A3 supertype allele positive prostate cancer patients |
JP2008145715A (en) * | 2006-12-08 | 2008-06-26 | Fujifilm Corp | Positive photosensitive composition, pattern forming method and thin film transistor array substrate |
WO2009022652A1 (en) * | 2007-08-16 | 2009-02-19 | Kurume University | Lck-derived peptide useful for cancer vaccine therapy on cancer patient who is positive for hla-a3 supertype allele |
GB0717864D0 (en) | 2007-09-13 | 2007-10-24 | Peptcell Ltd | Peptide sequences and compositions |
KR101512885B1 (en) | 2007-09-18 | 2015-04-16 | 가부시키가이샤 그린 펩티드 | Ctl inducer composition |
CA2804127A1 (en) | 2010-07-07 | 2012-01-12 | Green Peptide Co., Ltd. | Cancer peptide vaccine |
JP5911098B2 (en) | 2012-04-09 | 2016-04-27 | 国立研究開発法人情報通信研究機構 | Translation apparatus and program |
JP2014155132A (en) | 2013-02-13 | 2014-08-25 | Murata Mfg Co Ltd | Circuit board, and method of manufacturing the same |
RU2627175C2 (en) | 2013-03-08 | 2017-08-03 | Тайхо Фармасьютикал Ко., Лтд. | Novel peptide with 5 linked ctl epitopes |
-
2014
- 2014-10-20 TW TW103136214A patent/TWI651094B/en active
- 2014-10-20 MX MX2016004754A patent/MX2016004754A/en active IP Right Grant
- 2014-10-20 MY MYPI2016701424A patent/MY179119A/en unknown
- 2014-10-20 US US15/030,678 patent/US10137183B2/en active Active
- 2014-10-20 HU HUE14856540A patent/HUE050164T2/en unknown
- 2014-10-20 DK DK14856540.1T patent/DK3061771T3/en active
- 2014-10-20 JP JP2015543835A patent/JP6211093B2/en active Active
- 2014-10-20 CN CN201480057880.4A patent/CN105658673B/en active Active
- 2014-10-20 CA CA2927817A patent/CA2927817C/en active Active
- 2014-10-20 PL PL14856540T patent/PL3061771T3/en unknown
- 2014-10-20 SG SG11201603165TA patent/SG11201603165TA/en unknown
- 2014-10-20 AU AU2014337643A patent/AU2014337643B2/en active Active
- 2014-10-20 EP EP14856540.1A patent/EP3061771B1/en active Active
- 2014-10-20 PT PT148565401T patent/PT3061771T/en unknown
- 2014-10-20 ES ES14856540T patent/ES2796301T3/en active Active
- 2014-10-20 RU RU2016119567A patent/RU2636549C1/en active
- 2014-10-20 WO PCT/JP2014/077807 patent/WO2015060235A1/en active Application Filing
- 2014-10-20 KR KR1020167010131A patent/KR101913333B1/en active IP Right Grant
-
2016
- 2016-04-20 PH PH12016500742A patent/PH12016500742A1/en unknown
-
2017
- 2017-05-30 JP JP2017106390A patent/JP2017171678A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
HUE050164T2 (en) | 2020-12-28 |
JPWO2015060235A1 (en) | 2017-03-09 |
TWI651094B (en) | 2019-02-21 |
CN105658673A (en) | 2016-06-08 |
PH12016500742B1 (en) | 2016-06-20 |
JP6211093B2 (en) | 2017-10-11 |
AU2014337643B2 (en) | 2017-07-13 |
MX2016004754A (en) | 2016-07-22 |
EP3061771B1 (en) | 2020-04-15 |
US10137183B2 (en) | 2018-11-27 |
MY179119A (en) | 2020-10-28 |
EP3061771A1 (en) | 2016-08-31 |
CA2927817C (en) | 2019-02-26 |
BR112016008254A2 (en) | 2017-09-26 |
TW201601749A (en) | 2016-01-16 |
PT3061771T (en) | 2020-05-06 |
ES2796301T3 (en) | 2020-11-26 |
PH12016500742A1 (en) | 2016-06-20 |
AU2014337643A1 (en) | 2016-05-19 |
EP3061771A4 (en) | 2017-08-16 |
CA2927817A1 (en) | 2015-04-30 |
US20160235828A1 (en) | 2016-08-18 |
RU2636549C1 (en) | 2017-11-23 |
KR101913333B1 (en) | 2018-10-30 |
WO2015060235A1 (en) | 2015-04-30 |
CN105658673B (en) | 2019-07-26 |
DK3061771T3 (en) | 2020-07-13 |
KR20160055922A (en) | 2016-05-18 |
JP2017171678A (en) | 2017-09-28 |
PL3061771T3 (en) | 2020-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1216757A1 (en) | Peptide compound | |
EP2981543A4 (en) | Novel 4 7 peptide antagonists | |
EP2949750A4 (en) | Antibody-binding peptide | |
EP2976353A4 (en) | Autophagy-inducing peptide analogs | |
HRP20180452T1 (en) | Peptides | |
SG11201603165TA (en) | Novel Peptide Having 4 Linked CTL Epitopes | |
HK1211596A1 (en) | Peptide | |
HK1215440A1 (en) | Novel peptide having 5 linked ctl epitopes 5 ctl | |
HK1211595A1 (en) | Peptide | |
HK1198769A1 (en) | Novel peptide | |
GB201315130D0 (en) | Peptides | |
IL244956B (en) | Novel peptide compositions | |
GB201305465D0 (en) | Novel peptides | |
GB201316660D0 (en) | Peptides | |
GB201300381D0 (en) | Peptides |